Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients

YOSHIHIKO SHIBAYAMA1, TAKESHI KONDO2, HIROKI OHYA3, SHIN-ICHI FUJISAWA4, TAKANORI TESHIMA2 and KEN ISEKI3

1Education Research Center for Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, 2Department of Hematology, Graduate School of Medicine, and 3Laboratory of Clinical Pharmaceutics and Therapeutics, Graduate School of Pharmaceutical Sciences, Hokkaido University; 4Department of Clinical Laboratory, Hokkaido University Hospital, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan

Received November 30, 2014; Accepted February 3, 2015

DOI: 10.3892/or.2015.3839

Introduction

Acute myeloid leukemia (AML) is characterized by the clonal proliferation of myeloid precursors. Leukemic blasts or immature forms accumulate in the bone marrow, peripheral blood and occasionally in other tissues, resulting in variable reductions in the production of normal blood cells. Although some clinical factors such as age, performance status or a history of prior chemotherapy have been associated with the outcomes of patients with AML, the most important factor in predicting the risk of relapse has been chromosomal abnormalities detected at diagnosis (1-4). Proto-oncogene mutations are an important consideration in the risk stratification of patients with AML (5). The mutational diagnosis of NPM1, PML-RARA, CBFB-MYH11, FLT3 and RAS has been applied to clinical practice and has consequently impacted diagnoses, risk assessments and also guidance related to available therapies. Changes in the expression of specific genes (e.g., ABCB1, BAALC, ERG, MNL, JAK2 and WT1) appear to influence the prognoses of molecular subsets of patients with AML (3).

MicroRNAs (miRs) have been shown to negatively regulate gene expression by binding to mRNAs, and they play an important role in various physiological and pathological processes, such as apoptosis, cell proliferation and differentiation, which indicates their functionality in carcinogenesis as tumor-suppressor genes or proto-oncogenes (6). MicroRNA expression profiling has been used to distinguish between myeloid and lymphoid leukemia, as well as distinct cytogenetic subtypes of AML based on the upregulation or downregulation of specific miRNAs. MicroRNA expression signatures have also been correlated with recurrent molecular aberrations in AML (5). miR-126-5p is known to play an important role in various physiological processes. A previous study reported that miR-126-3p (accession no. MIMAT0000445) inhibited cell apoptosis and increased cell viability in AML cells (7). Mature miR-126-3p is generated from the stem-loop sequence miR-126 (accession no. MI0000471). Although miR-126 also generates mature
miR-126-5p (accession no. MIMAT0000444), its function is less clear.

Bioinformatics, microRNA.org, predicted that miR-126-5p targets Klotho. The klotho gene functions as an aging suppressor gene that extends the life-span. Recent studies have revealed that Klotho plays an important role in cancer tumorigenesis (8). The Klotho protein can regulate multiple growth factor signaling pathways, including IGF-1 and Wnt, as well as the activity of multiple ion channels (9,10). The overexpression of Klotho was previously shown to inhibit cancer cell proliferation and may act as a potential therapeutic strategy in cancers (8).

It currently remains unclear whether miR-126-5p is involved in the survival of patients with AML. The inhibitory effects of miR-126-5p on the expression of Klotho mRNA have not yet been elucidated in detail. We herein investigated the survival benefits of miR-126-5p in patients with AML and the inhibitory effects of a possible target mRNA of miR-126-5p and Klotho.

Materials and methods

Reagents. The TaqMan gene expression assays, siPORT NeoFX Transfection Agent and TR1zol reagent were obtained from Life Technologies (Carlsbad, CA, USA). The QuantiTect primer assay, miScript primer assay, miScript reverse transcription kit, synthetic microRNA mimic, QIAamp RNA Blood Mini kit, AllStars negative control siRNA and miScript SYBR-Green PCR kit were purchased from Qiagen (Valencia, CA, USA). Real-time PCR Master Mix Thunderbird SYBR qPCR Mix and reverse transcriptase, ReverTra Ace were purchased from Toyobo Co., Ltd., (Osaka, Japan). Protease inhibitor cocktail tablets (Complete, EDTA-free) were purchased from Roche Diagnostics GmbH (Buckinghamshire, UK). RPMI-1640 medium was purchased from Sigma-Aldrich (St. Louis, MO, USA). The human acute myelogenous leukemia cell line, KG-1 (JCRB0905), and the human myeloid leukemia cell line, KG-1 and K562, were grown in RPMI-1640 medium. The human proximal tubular cell line, HK-2, was grown in DMEM/Ham's F-12 medium. The medium was supplemented with 10% fetal bovine serum, 2 mM glutamine, and 100 units/ml of penicillin at 37°C in a 5% CO2 humidified atmosphere. The synthetic miRNA inhibitor and precursor were transfected using siPORT NeoFX transfection agent according to the manufacturer's protocol. In 96-well plates, 3 pmol of the inhibitor or precursor was transfected using 0.3 µl of the siPORT NeoFX and the cells were harvested 72 h later for the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Cytarabine and idarubicin were added to the wells and the cells were harvested at 120 and 48 h, respectively. The cells were incubated with MTT solution, and incubation was stopped with 20% sodium dodecyl sulfate solution. The 96-well plates were shaken overnight in the dark and the absorbance was then determined at 570 nm.

Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. The total RNA was isolated from the bone marrow using the QIAamp RNA Blood Mini kit according to the manufacturer's instructions. Single-stranded cDNA was synthesized by reverse-transcrip- tase using ReverTra Ace and single-stranded cDNA for the miRNA analysis was also synthesized by reverse-transcriptase using the miScript reverse transcription kit according to the manufacturer's instructions. Real-time PCR was performed on the LightCycler 480 II System (version 1.5; Roche Diagnostics GmbH, Mannheim, Germany) using TaqMan gene expression assays and Thunderbird qPCR Mix or the miScript SYBR-Green PCR kit according to the manufacturer's instructions. The comparative quantification cycle threshold (Cq) method was used to determine the relative expression levels of the target genes. Cq values were calculated by the 2nd derivative maximum method. Glucose-phosphate isomerase (GPI) and RN6U6B (U6) were analyzed as reference genes for mRNA and miR, respectively (13,14). The cycle number difference (ΔCq = reference genes - target genes) was calculated for each replicate. Relative target gene expression values were calculated using the mean of ΔCq from 3 replicates, μ(ΔCq) = 2^(-ΔCq/3) and expressed as 2^-μΔCq. (13).

Electrophoresis and western blot analysis. Protein sampling and the western blot analysis were performed as described previously (15). Whole cell homogenates (β-actin, 5 µg; other proteins, 20 µg) were separated using 10% SDS polyacrylamide
Table I. Patient characteristics.

| Gene    | Low | High | P-value |
|---------|-----|------|---------|
| miR-126-5p |     |      |         |
| Gender (M/F) | 29/25 | 31/24 | NS |
| Age, years | Mean | 58.2 | 57.3 |
| Range | 20-78 | 17-79 |
| Incipient (initial/relapse) | 50/4 | 51/4 | NS |
| M0 | 4 (7) | 2 (4) |
| M1 | 14 (26) | 8 (15) |
| M2 | 12 (22) | 21 (38) |
| M3 | 10 (19) | 5 (9) |
| M4 | 7 (13) | 10 (18) |
| MDS | 5 (9) | 1 (2) |
| Other | 2 (4) | 8 (14) |

A statistical analysis for single comparisons was performed using a two-tailed \( \chi^2 \) test. Comparisons between 2 groups were analyzed with the Mann-Whitney U test. NS, not significant; M, male; F, female.

Comparison of the overall survival and the expression levels of miR-126-5p and miR-126-3p. The relationship between miR-126-5p expression level and the overall survival duration in 109 patients who received intensive therapy was evaluated. Patients were divided into two groups: the high group expressed greater amounts of miR-126-5p than the median value of miR-126-5p expression while the low group expressed less. No significant differences were observed in the patient characteristics or gene mutation statuses of the high and low groups (Tables I and II). No significant differences were observed in the expression levels of RNA-related abnormalities in AML between the two groups (Table III). Higher miR-126-5p expression levels (more than the median value) correlated with a poorer probability of overall survival (Fig. 1A). Higher miR-126-3p expression levels also correlated with a poorer overall survival (Fig. 1B). Cox proportional hazards models also estimated a significant higher hazard ratio (HR) of miR-126-5p and miR-126-3p in the high expression group (Fig. 1). In the Cox proportional hazard regression model, the ‘miR-126-5p x miR-126-3p’ interaction was not significant (p=0.73).

Effects of miR-126-5p transfection on drug sensitivity, Klotho expression and Akt phosphorylation. The miR-126-5p mimic was transfected into the human cell lines, KG-1, K562 and HK-2. Transfection of the miR-126-5p mimic into the KG-1 cells resulted in decreased sensitivity to cytarabin, but not to idarubicin. Transfection of the miR-126-5p inhibitor did not alter the drug sensitivity (Table IV). The expression level of Klotho mRNA was decreased following transfection with the miR-126-5p mimic. Transfection of the miR-126-5p mimic also significantly decreased the expression levels of the Klotho protein (relative expression level; control, 1.00±0.03; miR-126-5p mimic, 0.61±0.13, mean ± standard error; p=0.046, Student’s t-test, n=3). A typical western blot analysis is shown in Fig. 2A. The transfection of the miR-126-5p mimic as well as the positive control siRNA downregulated the expression of Klotho (Fig. 2A). The same actions were observed in the K562 and HK-2 cells (Fig. 2B). Azuma et al reported that Klotho mRNA and protein are abundantly expressed in HK-2 cells (30); thus, the transfection effect of miR-126-5p into HK-2 cells was also evaluated. Transfections of the miR-126-5p mimic into KG-1 or K562 cells as well as into the HK-2 cells downregulated the expression of Klotho. The expression level of Klotho mRNA was also decreased by the transfection with the miR-126-5p mimic in the K562
Expression levels of the Klotho protein were decreased by the transfection with the miR-126-5p mimic in the HK-2 cells (Fig. 2B). Transfection of the miR-126-5p mimic resulted in an elevation in the phosphorylation of Akt in the KG-1 cells (Fig. 2C). Transfection of the miR-126-5p mimic also significantly increased the expression of the phosphorylated forms of Akt in the HK-2 cells (relative expression level: control, 1.00±0.14; miR-126-5p mimic, 2.22±0.25, mean ± standard error; p=0.005, Student’s t-test, n=4; Fig. 2D). Transfection of the miR-126-5p mimic or inhibitor did not affect the expression or phosphorylation of JAK2, STAT3, STAT5 or Actin (Fig. 2C), or the mRNA expression of ABCB1, BAALC, ERG, MN1, JAK2, WT1 or ACTB (data not shown).

Discussion

The present study revealed two important issues: Firstly, higher levels of miR-126-5p/3p resulted in a poorer prognosis and secondly, miR-126-5p suppressed the expression of Klotho mRNA. One hundred and nine eligible patients who received intensive therapy were enrolled in the present study. Patients were divided into high and low groups based on their miR-126-5p expression levels. No significant differences were observed in the patient characteristics or the gene mutation statuses between the high and low groups. No significant differences were observed in the expression levels of gene-related abnormalities in AML between the two groups (Table III). These results suggest that the expression levels of the gene-related abnormalities were not related to prognosis in these groups.

The high expression group had a poorer prognosis than that of the low group (Fig. 1). The functions of miR-126-5p have been reported previously in an in vitro study; the

| Table III. Relative expression levels of the gene-related abnormalities in AML. |
|----------------------------------------|-----------|-----------|-----------|
| Gene        | miR-126-5p Low | miR-126-5p High | P-value |
|-------------|----------------|----------------|---------|
| ABCB1       | 0.055±0.128    | 0.027±0.061    | NS      |
| BAALC       | 0.589±1.836    | 0.927±2.034    | NS      |
| ERG         | 0.25±0.346     | 0.184±0.190    | NS      |
| MN1         | 0.137±0.493    | 0.117±0.215    | NS      |
| JAK2        | 0.58±0.813     | 0.40±0.525     | NS      |
| WT1         | 2.98±4.832     | 2.25±2.511     | NS      |

Values are represented as the mean ± standard deviation. Comparisons between the 2 groups were performed with the Mann-Whitney U test. NS, not significant. Relative expression levels were evaluated using glucose-phosphate isomerase (GPI) as a reference gene.

Figure 1. Kaplan-Meier overall survival curves for patients with AML according to the low and high expression of miR-126-5p and miR-126-3p. Kaplan-Meier plots showing estimates of overall survival probabilities grouped based on the miR-126-5p expression levels in a completely independent set of 109 AML patients. (A) The black line curve represents the samples with high (above median, 2-ΔΔCq value >1.1x10^-4, n=55) miR-126-5p expression levels, whereas the dotted line curve corresponds to the samples with low (below median, 2-ΔΔCq value <1.1x10^-4, n=54) miR-126-5p expression levels. (B) The black line curve represents the samples with high (above median, 2-ΔΔCq value >2.0x10^-4, n=54) miR-126-3p expression levels, whereas the dotted line curve corresponds to the samples with low (below median, 2-ΔΔCq value <2.0x10^-4, n=54) miR-126-3p expression levels. Comparisons between each group were performed with the log-rank test. Cox proportional hazards models also estimated a significantly higher HR of miR-126-5p and miR-126-3p in the high group: miR-126-5p: HR=2.096 (95% CI, 1.075-4.228), p=0.030 and miR-126-3p: HR=1.958 (95% CI, 1.001-3.927), p=0.049. In the Cox proportional hazard regression model, the 'miR-126-5p x miR-126-3p' interaction was not significant (p=0.73). CI, confidence interval; AML, acute myeloid leukemia; HR, hazard ratio.

| Table IV. Effects of the mimic or inhibitor miR-126-5p transfection on drug sensitivity in the KG-1 cells. |
|--------------------------------------------------------|-----------|-----------|-----------|
| miR-126-5p Mimic or Inhibitor | NC | Mimic | Inhibitor |
| Idarubicin | 38.0±1.6 | 43.8±2.4 | 46.0±1.6 | |
| Cytarabin | 35.1±7.1 | 54.0±5.3 | 36.6±2.5 | |

The control group was transfected with negative control RNA. Values are represented as the mean ± standard error. Comparisons with the negative control group were performed with the Tukey-Kramer test. *p<0.05. NC, negative control.
miR-126-3p mimic was shown to inhibit cell apoptosis, increase cell viability and enhance proliferation and differentiation (7,16-19). These findings suggest that the upregulation of miR-126-3p is a predictor for poor prognosis. This was the first study to suggest that higher expression of miR-126-3p results in a poorer prognosis in AML patients. The present study showed that the high group had a poorer prognosis and an interaction was not observed between the hazard ratios of miR-126-5p and miR-126-3p (p=0.73). These results suggest that the upregulation of miR-126-5p may enhance the malignant potential of AML.

Recent studies have shown that miR-126-5p rescued the proliferation of endothelial cells by suppressing Dlk1, and decreased the proliferation of stromal cells (20-22). The over-
expression of miR-126-3p/5p was shown to significantly induce apoptosis, and activate caspase-3 and caspase-7 by directly regulating ADAM9 and MMP7 in melanoma (23). These findings suggested that the upregulation of miR-126-5p resulted in opposing effects in different cell types; miR-126-5p inhibited proliferation in stromal cells, but activated proliferation in endothelial cells and inhibited apoptosis in melanoma cells. In the present study, the transfection of miR-126-5p into KG-1 cells induced drug resistance to cytarabine (Table IV) and the higher expression of miR-126-5p was associated with a poorer prognosis. The results of the present study revealed that the higher expression of miR-126-5p inhibited apoptosis induced by the cytarabine treatment, leading to a poor prognosis.

Bioinformatic, microRNA.org (http://www.micronorna.org), is a comprehensive resource of microRNA target predictions and expression profiles. Target predictions are based on the development of a miRanda algorithm, which incorporates current biological knowledge on target rules and on the use of an up-to-date compendium of mammalian microRNAs (24). Klotho has been identified as an aging gene, and also plays an important role in cancer tumorigenesis, cell survival, differentiation and metastasis (8). Wang et al reported that the knockdown of Klotho inhibited apoptosis, which significantly increased the expression of phospho-Akt and increased resistance to cisplatin in A549/DDP cells (11). A previous study reported that Klotho exerted an inhibitory effect on the IGF-1 pathway in both breast and pancreatic cancer cells (25-27). The PI3K/Akt pathway is one of the important downstream pathways of the IGF-1 pathway, and numerous studies have confirmed its role in the apoptosis of cancer cells (28-30). The present study demonstrated that miR-126-5p inhibited the expression of Klotho and upregulated the phosphorylation of Akt (Fig. 2). The present study and the previous findings collectively suggest that miR-126-5p may induce drug resistance by activating phospho-Akt, which targets Klotho.

In conclusion, the results of the present study demonstrated that the higher expression of miR-126-5p/3p in AML may result in a poor prognosis. Furthermore, miR-126-5p-induced drug resistance to cytarabine by enhancing phosphorylation of Akt.

Acknowledgements

The authors would like to thank all the patients who provided bone marrow samples, as well as patient information, medical and nursing staff working at the North Japan Hematology Study Group: The principal investigators of the study, in alphabetical order by city: Asahikawa - Y. Kakinoki (Asahikawa City Hospital); Hakodate - Y. Tsutsumi (Hakodate Municipal Hospital), T. Kawamura (Nanae New Hospital); Kushiro - T. Miyagishima (Kushiro Rosai Hospital); Obihiro - H. Kobayashi (Obihiro-Kosei Hospital); Sapporo - A. Shigematsu, M. Nishio (Hokkaido University Hospital), H. Iwasaki (Sapporo-Kosei General Hospital), K. Imai (Sapporo Hokkaido University Hospital), M. Kurosawa (National Hospital Organization, Hokkaido Cancer Center), M. Moroika, A. Mori (Aiku Hospital), S. Yamamoto (Sapporo City General Hospital), Y. Haseyama (KKR Sapporo Medical Center Tonan Hospital); Toyama - A. Wada (Toyama University Hospital). The authors would like to thank Drs. Kumiko Kasashi and Takehiro Yamada at the Department of Pharmacy, Hokkaido University Hospital, for their helpful contributions. The present study was supported by the Shimabara Science Promotion Foundation and the Training Program for Oncology Professionals in Hokkaido by the Ministry of Education, Culture, Sports Science and Technology, Japan.

References

1. Mrózek K, Heerema NA and Bloomfield CD: Cytogenetics in acute leukemias. Blood Rev 18: 115-136, 2004.
2. Burnett A, Wetzler M and Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494, 2011.
3. Marcucci G, Haferlach T and Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic Implications. J Clin Oncol 29: 475-486, 2011.
4. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100: 4325-4336, 2002.
5. Walker A and Marcucci G: Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol 5: 547-558, 2012.
6. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
7. Li Z, Lu J, Sun M, et al: Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105: 15535-15540, 2008.
8. Zhou X and Wang X: Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol: Aug 3, 2014 (Epub ahead of print).
9. Kuro-o M: Klotho as a regulator of oxidative stress and senescence. J Biol Chem 389: 233-241, 2008.
10. Hu MC, Shiizaki Y, Kuro-o M and Moe OW: Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75: 503-533, 2013.
11. Wang Y, Chen L, Huang G, et al: Klotho sensitizes human lung cancer cell line to cisplatin via PI3K/Akt pathway. PLoS One 8: e57391, 2013.
12. Liu F, Wu S, Ren H and Gu J: Klotho suppresses RIG-1-mediated senescence-associated inflammation. Nat Cell Biol 13: 254-262, 2011.
13. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102: 1613-1618, 2003.
14. Fukao T, Fukuda Y, Kiga K, et al: An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 129: 617-631, 2007.
15. Shibayama Y, Ishashita Y, Yoshikawa Y, et al: Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats. Biol Pharm Bull 34: 1418-1425, 2011.
16. Zang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ and Ma D: The cell growth suppressor, miR-126, targets IRS-1. Biochem Biophys Res Commun 377: 136-140, 2008.
17. Ebihara F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol 96: 98-107, 2004.
18. Shen WF, Hu YL, Uttarwar L, Passegue E and Largman C: MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol Cell Biol 28: 4609-4619, 2008.
19. Cammarata G, Augugliaro L, Salemi D, et al: Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 85: 331-339, 2010.
20. Schober A, Nazari-Jahantigh M, Wei Y, et al: 2014. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing DKK1. J Nat Med 20: 368-374, 2014.
21. Wu Z, Yin H, Liu T, et al: MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13. Biochem Biophys Res Commun 443: 944-949, 2014.
22. Zhou W, Yin H, Wang T, et al: MiR-126-5p regulates osteolysis formation and stromal cell proliferation in giant cell tumor through inhibition of PTEN. Bone 66: 267-276, 2014.
23. Felli N, Felicetti F, Lustri AM, et al: miR-126&126* restored expression play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 8: e56824, 2013.
24. Betel D, Wilson M, Gabow A, Marks DS and Sander C: 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36: D149-D153, 2008.
25. Wolf I, Levanon-Cohen S, Bose S, et al: Klotho: a tumor suppressor and a modulator of the IGF-I and FGF pathways in human breast cancer. Oncogene 27: 7094-7105, 2008.
26. Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B and Wolf I: KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 17: 4254-4266, 2011.
27. Chen B, Wang X, Zhao W and Wu J: Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29: 99, 2010.
28. Poh TW and Pervaiz S: LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 65: 6264-6274, 2005.
29. Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994, 2000.
30. Shibata T, Kokubu A, Tsuta K and Hirohashi S: Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 283: 203-211, 2009.